In recent years, there have been warnings for the use of SGLT-2 Inhibitors that suggest an increased risk of fracture, particularly when placed on one SGLT2 inhibitor, canagliflozin (Invokana). In 2015, the US FDA added a warning on canagliflozin, indicating that patients on canagliflozin must use caution because of a fracture risk associated with the diabetes medication. Now, researchers are suggesting this may not be the case. Read more